EZH1/2 inhibition improves immunotherapy response through MHC Class II de-repression and neutrophil reprogramming.

Saved in:
Bibliographic Details
Title: EZH1/2 inhibition improves immunotherapy response through MHC Class II de-repression and neutrophil reprogramming.
Authors: Childress AR; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington KY, United States., Esoe DP; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington KY, United States., Song X; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington KY, United States., Gosser CM; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington KY, United States., Lin Y; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington KY, United States., Plaugher DR; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington KY, United States., DuCote TJ; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington KY, United States., Naughton KJ; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington KY, United States., Skaggs EM; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington KY, United States., Yang H; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington KY, United States., Goettl R; Markey Cancer Center, University of Kentucky, Lexington KY, United States., Liu J; Markey Cancer Center, University of Kentucky, Lexington KY, United States.; Division of Cancer Biostatistics, Department of Internal Medicine, University of Kentucky, Lexington, KY, United States., Hao Z; Markey Cancer Center, University of Kentucky, Lexington KY, United States.; Division of Oncology, Department of Internal Medicine, University of Kentucky, Lexington KY, United States., Fliss AE; Daiichi Sankyo, Co., Ltd, Basking Ridge, NJ, United States., Honma D; Oncology Laboratories, Daiichi Sankyo Co., Ltd, Tokyo, Japan., Burus T; Markey Cancer Center, University of Kentucky, Lexington KY, United States.; Division of Cancer Biostatistics, Department of Internal Medicine, University of Kentucky, Lexington, KY, United States.; Kentucky Cancer Registry, Markey Cancer Center, University of Kentucky, Lexington KY, United States., Lei F; Markey Cancer Center, University of Kentucky, Lexington KY, United States.; Division of Cancer Biostatistics, Department of Internal Medicine, University of Kentucky, Lexington, KY, United States.; Kentucky Cancer Registry, Markey Cancer Center, University of Kentucky, Lexington KY, United States., Huang B; Markey Cancer Center, University of Kentucky, Lexington KY, United States.; Division of Cancer Biostatistics, Department of Internal Medicine, University of Kentucky, Lexington, KY, United States.; Kentucky Cancer Registry, Markey Cancer Center, University of Kentucky, Lexington KY, United States., Beswick EJ; Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, United States., Brainson CF; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington KY, United States.; Markey Cancer Center, University of Kentucky, Lexington KY, United States.
Source: BioRxiv : the preprint server for biology [bioRxiv] 2026 Jul 02. Date of Electronic Publication: 2026 Jul 02.
Publication Type: Journal Article; Preprint
Journal Info: Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2692-8205
DOI:10.64898/2026.06.01.725956